Medexus Pharmaceuticals Inc. (TSX:MDP)

Market Cap	151.79M +72.8%
Revenue (ttm)	146.70M -2.2%
Net Income	-3.36M
EPS	-0.10
Shares Out	31.43M
PE Ratio	n/a
Forward PE	12.52
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,080
Open	4.800
Previous Close	4.820
Day's Range	4.770 - 4.890
52-Week Range	2.510 - 5.500
Beta	1.73
Analysts	Strong Buy
Price Target	7.25 (+50.1%)
Est. Earnings	Nov 4, 2026

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis, psoriasis, and juvenile idiopathic arthritis; Rupall, a prescription allergy medication; and GRAF...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 90
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: MDP

Financial Performance

Financial numbers in USD

Analyst Summary

According to 6 analysts, the average rating for MDP stock is "Strong Buy." The 12-month stock price target is $7.25, which is an increase of 50.10% from the latest price.

Price Target

$7.25

(50.10% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and QUODD

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by QUODD.

Last checked:

Oct 14, 2026

Data Sources Report a data error